Pharmacy: Addressing substance use in the 21st century

References

• Manolakis PG, Skelton JB. Pharmacists’ contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers. Am J Pharm Educ. 2010;74(10):S7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058447/.
   PubMedGoogle Scholar
• Brenan M. Nurses again outpace other professions for honesty, ethics. Gallup.com.https://news.gallup.com/poll/245597/nurses-again-outpace-professions-honesty-ethics.aspx. Published December 20, 2018.
   Google Scholar
• Anderson SL, Marrs JC. A Review of the role of the pharmacist in heart failure transition of care. Adv Ther. 2018;35(3):311–323.
   PubMed Web of Science ®Google Scholar
• Fazel MT, Bagalagel A, Lee JK, Martin JR, Slack MK. Impact of diabetes care by pharmacists as part of health care team in ambulatory settings: A systematic review and meta-analysis. Ann Pharmacother. 2017;51(10):890–907.
   PubMed Web of Science ®Google Scholar
• Kennelty KA, Polgreen LA, Carter BL. Team-based care with pharmacists to improve blood pressure: A review of recent literature. Curr Hypertens Rep. 2018;20(1):1.
   PubMed Web of Science ®Google Scholar
• Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann Intern Med. 2017;167(5):293.
   PubMed Web of Science ®Google Scholar
• Jones CM. The paradox of decreasing nonmedical opioid analgesic use and increasing abuse or dependence - An assessment of demographic and substance use trends, United States, 2003–2014. Addict Behav. 2017;65:229–235.
   PubMed Web of Science ®Google Scholar
• Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49(4):493–501.
   PubMed Web of Science ®Google Scholar
• Garg RK, Fulton-Kehoe D, Franklin GM. Patterns of opioid use and risk of opioid overdose death among medicaid patients. Med Care. 2017;55(7):661–668.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM, Centers for Disease Control and Prevention (CDC). Controlled substance prescribing patterns–Prescription Behavior Surveillance System, Eight States, 2013. MMWR Surveill Summ. 2015;64(No. SS-9):1–14.
   PubMed Web of Science ®Google Scholar
• Guy GP, Pasalic E, Zhang K. Emergency department visits involving opioid overdoses, U.S., 2010–2014. Am J Prev Med. 2018;54(1):e37–e39.
   PubMed Web of Science ®Google Scholar
• Vivolo-Kantor AM, Seth P, Gladden RM. Vital signs: trends in emergency department visits for suspected opioid overdoses – United States, July 2016–September 2017. MMWR Morb Mortal Wkly Rep. 2018;67(9):279–285.
   PubMed Web of Science ®Google Scholar
• Vivolo-Kantor AM, Hoots B, David F, Gladden RM. Suspected heroin overdoses in U.S. emergency departments, 2017–2018. Am J Public Health. 2019;109:1022–1024.
   PubMed Web of Science ®Google Scholar
• Weiss AJ. (Truven Health Analytic), Elixhauser A (AHRQ), Barrett ML (M.L. Barrett, Inc.), Steiner CA (AHRQ), Bailey MK (Truven Health Analytics), O’Malley L (Truven Health Analytics). Opioid-Related Inpatient Stays and Emergency Department Visits by State, 2009–2014. Rockville, MD: Agency for Healthcare Research and Quality; 2016. HCUP Statistical Brief #219. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb219-Opioid-Hospital-Stays-ED-Visits-by-State.pdf. Accessed August 24, 2019.
   Google Scholar
• Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths – United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–1427.
   PubMedGoogle Scholar
• Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths – United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445–1452.
   PubMed Web of Science ®Google Scholar
• Lindley B, Cox N, Cochran G. Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: a review. IPRP. 2019;8:85–96.
   Google Scholar
• Skoy E, Eukel H, Werremeyer A, Strand M, Frenzel O, Steig J. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose. J Am Pharm Assoc 2003. 2019. doi: 10.1016/j.japh.2019.09.003.
   Google Scholar
• Cochran G, Chen Q, Field C, et al. A community pharmacy-led intervention for opioid medication misuse: a small-scale randomized clinical trial. Drug Alcohol Depend. 2019;205:107570.
   PubMed Web of Science ®Google Scholar
• Kurian S, Baloy B, Baird J, et al. Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians. J Am Pharm Assoc 2003. 2019;59(6):824–831.
   PubMed Web of Science ®Google Scholar
• Laliberté M-C, Perreault S, Damestoy N, Lalonde L. Ideal and actual involvement of community pharmacists in health promotion and prevention: a cross-sectional study in Quebec, Canada. BMC Public Health. 2012;12(1):192.
   PubMed Web of Science ®Google Scholar
• Morrill AM, Abel CA, Januszweski M, Chamberlain B. Community education by advanced pharmacy practice experience students: increasing electronic cigarette awareness amongst teens. Curr Pharm Teach Learn. 2017;9(6):1147–1150.
   PubMed Web of Science ®Google Scholar
• McBane SE, Corelli RL, Albano CB, et al. The role of academic pharmacy in tobacco cessation and control. Am J Pharm Educ. 2013;77(5):93.
   PubMed Web of Science ®Google Scholar
• Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2015;28(4):404–412.
   PubMedGoogle Scholar
• Cochran G, Gordon AJ, Field C, et al. Developing a framework of care for opioid medication misuse in community pharmacy. Res Social Adm Pharm. 2016;12(2):293–301.
   PubMed Web of Science ®Google Scholar
• Cochran G, Hruschak V, DeFosse B, Hohmeier KC. Prescription opioid abuse: pharmacists’ perspective and response. IPRP. 2016;5:65–73.
   Google Scholar
• Fitzgerald N, Watson H, McCaig D, Stewart D. Developing and evaluating training for community pharmacists to deliver interventions on alcohol issues. Pharm World Sci. 2009;31(2):149–153.
   PubMed Web of Science ®Google Scholar
• McCaig D, Fitzgerald N, Stewart D. Provision of advice on alcohol use in community pharmacy: a cross-sectional survey of pharmacists’ practice, knowledge, views and confidence. Int J Pharm Pract. 2011;19(3):171–178.
   PubMedGoogle Scholar
• Adhikari SB. Screening, Intervention and Referral Practices among Prescribers and Pharmacists Treating Patients with Substance Abuse Disorder in Ohio. Columbus, OH: Ohio Mental Health and Addiction Services; 2014.
   Google Scholar
• Hattingh HL, Hallett J, Tait RJ. Making the invisible visible” through alcohol screening and brief intervention in community pharmacies: an Australian feasibility study. BMC Publ Health. 2016;16(1):1141.
   PubMedGoogle Scholar
• Hwang J, Arneson T, St Peter W. Minnesota pharmacists and medical vannabis: a survey of knowledge, concerns, and interest prior to program launch. P T 2016;41(11):716–722. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083080/. Accessed August 24, 2019.
   PubMedGoogle Scholar
• Isaac S, Saini B, Chaar BB. The role of medicinal cannabis in clinical therapy: pharmacists’ perspectives. PLoS One. 2016;11(5):e0155113.
   PubMed Web of Science ®Google Scholar
• Seamon MJ, Fass JA, Maniscalco-Feichtl M, Abu-Shraie NA. Medical marijuana and the developing role of the pharmacist. Am J Health Syst Pharm. 2007;64(10):1037–1044.
   PubMed Web of Science ®Google Scholar
• Pharmacists take on medical cannabis dispensing role in three states | American Pharmacists Association. http://www.pharmacist.com/article/pharmacists-take-medical-cannabis-dispensing-role-three-states. Accessed August 24, 2019.
   Google Scholar
• Bachyrycz A, Shrestha S, Bleske BE, Tinker D, Bakhireva LN. Opioid overdose prevention through pharmacy-based naloxone prescription program: innovations in health care delivery. Subst Abuse. 2017;38(1):55–60.
   PubMed Web of Science ®Google Scholar
• Bailey AM, Wermeling DP. Naloxone for opioid overdose prevention: pharmacists’ role in community-based practice settings. Ann Pharmacother. 2014;48(5):601–606.
   PubMed Web of Science ®Google Scholar
• Muzyk A, Smothers ZPW, Collins K, MacEachern M, Wu L-T. Pharmacists’ attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature. Subst Abuse. 2019;1–8. doi: 10.1080/08897077.2019.1616349.
   Web of Science ®Google Scholar
• Thornton JD, Lyvers E, Scott VGG, Dwibedi N. Pharmacists’ readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc (2003). 2017;57(2):S12–S18.e4.
   PubMed Web of Science ®Google Scholar
• Freeman PR, Goodin A, Troske S, Strahl A, Fallin A, Green TC. Pharmacists’ role in opioid overdose: Kentucky pharmacists’ willingness to participate in naloxone dispensing. J Am Pharm Assoc (2003). 2017;57(2):S28–S33.
   PubMed Web of Science ®Google Scholar
• Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J. 2015;12(1):25.
   PubMedGoogle Scholar
• Winstanley EL, Mashni R, Schnee S, Miller N, Mashni SM. The development and feasibility of a pharmacy-delivered opioid intervention in the emergency department. J Am Pharm Assoc. 2017;57(2):S87–S91.
   Google Scholar
• Meyerson BE, Davis A, Agley JD, et al. Predicting pharmacy syringe sales to people who inject drugs: policy, practice and perceptions. Int J Drug Pol. 2018;56:46–53.
   PubMed Web of Science ®Google Scholar
• Pollini RA. Self-reported participation in voluntary nonprescription syringe sales in California’s Central Valley. J Am Pharm Assoc. 2017;57(6):677–685.
   Google Scholar
• Goodin A, Fallin-Bennett A, Green T, Freeman PR. Pharmacists’ role in harm reduction: a survey assessment of Kentucky community pharmacists’ willingness to participate in syringe/needle exchange. Harm Reduct J. 2018;15(1):4. doi: 10.1186/s12954-018-0211-4.
   PubMedGoogle Scholar
• Ghaddar A, Nassar K, Elsoury G. Barriers to access to sterile syringes as perceived by pharmacists and injecting dDrug users: Implications for harm reduction in Lebanon. Subst Use Misuse. 2017;52(11):1420–1428.
   PubMed Web of Science ®Google Scholar
• Stopka TJ, Donahue A, Hutcheson M, Green TC. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc. 2017;57(2):S34.
   Google Scholar
• Chiarello E. Nonprescription syringe sales: resistant pharmacists’ attitudes and practices. Drug Alcohol Depend. 2016;166:45–50.
   PubMed Web of Science ®Google Scholar
• Stopka TJ, Geraghty EM, Azari R, Gold EB, Deriemer K. Factors associated with presence of pharmacies and pharmacies that sell syringes over-the-counter in Los Angeles County. J Urban Health. 2013;90(6):1079–1090.
   PubMed Web of Science ®Google Scholar
• Paquette CE, Pollini RA. Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: a systematic review. Drug Alcohol Depend. 2018;188:239–250.
   PubMed Web of Science ®Google Scholar
• Pollini RA, Rudolph AE, Case P. Nonprescription syringe sales: a missed opportunity for HIV prevention in California. J Am Pharm Assoc. 2015;55(1):31–40.
   Google Scholar
• Rich JD, Martin EG, Macalino GE, Paul RV, McNamara S, Taylor LE. Pharmacist support for selling syringes without a prescription to injection drug users in Rhode Island. J Am Pharm Assoc (Wash). 2002;42(6):S58–S61.
   PubMedGoogle Scholar
• Bratberg JP, Smothers ZPW, Collins K, Erstad B, Ruiz Veve J, Muzyk AJ. Pharmacists and the opioid crisis: a narrative review of pharmacists’ practice roles. J Am Coll Clin Pharm. 2019;1–7. doi: 10.1002/jac5.1171.
   Google Scholar
• DiPaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc (2003). 2015;55(2):187–192.
   PubMed Web of Science ®Google Scholar
• Collins S. Pharmacy resident Blaiklock addresses opioid crisis in Kentucky. Pharm Today. 2016;22(10):70.
   Google Scholar
• American Pharmacists Association. Keep making noise about how pharmacists are fighting the opioid crisis [Web page]. https://www.pharmacist.com/CEOBlog/keep-making-noise-about-how-pharmacists-are-fighting-opioid-crisis. Accessed August 24, 2019.
   Google Scholar
• United States Congress House. Committee on Energy and Commerce Oversight and Investigation. Hearing on Examining the Growing Problems of Prescription Drug and Heroin Abuse: State and Local Perspectives. March 26, 2015. 114th Congress. 1st session. Washington: GPO, 2015 (statement of Sarah T. Melton, PharmD, BCPP, BCACP, CGP, FASCP. Chair, One Care of Southwest Virginia, Associate Professor of Pharmacy Practice, East Tennessee State University Gatton College of Pharmacy). http://docs.house.gov/meetings/IF/IF02/20150326/103254/HHRG-114-IF02-Wstate-MeltonS-20150326.pdf. Accessed August 24, 2019.
   Google Scholar
• United States Congress House. Committee on Ways and Means, Subcommittee on Health. Hearing on The Opioid Crisis: Removing Barriers to Prevent and Treat Opioid Abuse and Dependence in Medicare. February 6, 2018. 115th Congress. 2nd session. Washington: GPO, 2018 (statement of Laura Hungiville, Chief Pharmacy Office, WellCare Health Plans, Inc). https://waysandmeans.house.gov/wp-content/uploads/2018/02/20180206HL-Testimony-Hungiville.pdf. Accessed August 24, 2019.
   Google Scholar
• Hill LG, Evoy KE, Reveles KR. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. J Am Pharm Assoc (2003). 2019;59(6):779–782.
   PubMed Web of Science ®Google Scholar
• Adams JM. Increasing naloxone awareness and use: the role of health care practitioners. JAMA 2018;319(20):2073.
   PubMed Web of Science ®Google Scholar
• Reynolds V, Causey H, McKee J, Reinstein V, Muzyk A. The role of pharmacists in the opioid epidemic: An examination of pharmacist-focused initiatives across the United States and North Carolina. N C Med J. 2017;78(3):202–205.
   PubMedGoogle Scholar
• Thakur T, Frey M, Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review. J Am Pharm Assoc (2003). 2019. doi: 10.1016/j.japh.2019.06.016.
   PubMedGoogle Scholar
• Compton WM, Jones CM, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the U.S. opioid crisis. Res Soc Admin Pharm. 2019;15(8):910–916.
   PubMed Web of Science ®Google Scholar
• Fendrich M, Bryan JK, Hooyer K. Prescription drug monitoring programs and pharmacist orientation toward dispensing controlled substances. Subst Use Misuse. 2018;53:1324–1330.
   PubMed Web of Science ®Google Scholar
• Meyerson BE, Ryder PT, Richey-Smith C. Achieving pharmacy-based public health: a call for public health engagement. Public Health Rep. 2013;128(3):140–143.
   PubMed Web of Science ®Google Scholar
• Hartung DM, Hall J, Haverly SN, et al. Pharmacists’ role in opioid safety: a focus group investigation. Pain Med. 2018;19(9):1799–1806.
   PubMed Web of Science ®Google Scholar
• Tuchman E, Gregory C, Simson M, Drucker E. Safety, efficacy, and feasibility of office-based prescribing and community pharmacy dispensing of methadone: results of a pilot study in New Mexico. Addict Disord Their Treat. 2006;5(2):43–51.
   Google Scholar
• Fleming ML, Barner JC, Brown CM, Shepherd MD, Strassels SA, Novak S. Pharmacists’ training, perceived roles, and actions associated with dispensing controlled substance prescriptions. J Am Pharm Assoc (2003). 2014;54(3):241–250.
   PubMed Web of Science ®Google Scholar
• Price ET. Demonstrated value in the public health arena: pharmacist roles in addressing the current opioid crisis. J Am Pharm Assoc (2003). 2017;57(5):566–567.
   PubMed Web of Science ®Google Scholar
• Muzyk AJ, Peedin E, Lipetzky J, Parker H, McEachern MP, Thomas K. Substance use education in US schools of pharmacy: a systematic review of the literature. Subst Abus. 2017;38(4):455–463.
   PubMed Web of Science ®Google Scholar
• Muzyk AJ, Tew C, Thomas-Fannin A, et al. An interprofessional course on substance use disorders for health professions students. Acad Med. 2017;92(12):1704–1708.
   PubMed Web of Science ®Google Scholar
• Muzyk A, Mullan P, Andolsek KM, et al. An interprofessional substance use disorder course to improve students’ educational outcomes and patients’ treatment decisions. Acad Med. 2019. 94:1792–1799.
   PubMed Web of Science ®Google Scholar
• Thomas K, Muzyk AJ. Surveys of substance use disorders education in US pharmacy programs. Mental Health Clin. 2018;8(1):14–17.
   PubMedGoogle Scholar
• Bachyrycz A, Takeda MY, Wittstrom K, Bleske B. Opioid overdose response training in pharmacy education: An analysis of students’ perception of naloxone use for opioid overdose prevention. Curr Pharm Teach Learn. 2019;11(2):166–171.
   PubMed Web of Science ®Google Scholar
• Bakhireva LN, Bautista A, Cano S, Shrestha S, Bachyrycz AM, Cruz TH. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists. Subst Abuse. 2017;39:331–341.
   Web of Science ®Google Scholar
• Anderson SM, Geyer S, Cailor SM, Chen A. Impact of a team-based learning drug misuse education training program on student pharmacists’ confidence. Curr Pharm Teach Learn. 2019;11(1):58–65.
   PubMed Web of Science ®Google Scholar
• Countey H, Steinbronn C, Grady SE. Changing student attitudes and perceptions toward opioid use disorder. Mental Health Clin. 2018;8(5):222–226.
   PubMedGoogle Scholar
• Dowling K, Mospan CM, Subedi P, Hagemeier NE. Explaining pharmacy students’ dispensing intentions in substance abuse-related gray areas using the theory of planned behavior. Am J Pharm Educ. 2018;83(5):6767.
   Web of Science ®Google Scholar
• Eukel HN, Skoy E, Werremeyer A, Burck S, Strand M. Changes in pharmacists’ perceptions after a training in opioid misuse and accidental overdose prevention. J Contin Educ Health Prof. 2019;39(1):7–1.
   PubMed Web of Science ®Google Scholar
• Fleming ML, Bapat SS, Varisco TJ. Using the theory of planned behavior to investigate community pharmacists’ beliefs regarding engaging patients about prescription drug misuse. Res Soc Adm Pharm. 2019;15(8):992–999.
   PubMed Web of Science ®Google Scholar
• Haslam L, Gardner DM, Murphy AL. A retrospective analysis of patient care activities in a community pharmacy mental illness and addictions program. Res Soc Adm Pharm. 2019. doi: 10.1016/j.sapharm.2019.07.003.
   PubMedGoogle Scholar
• Hines J, Deja E, Black EP. Student pharmacist perceptions of participation in hands-on naloxone counseling. Curr Pharm Teach Learn. 2018;10(6):712–716.
   PubMed Web of Science ®Google Scholar
• Lai Joyce Chun K, Olsen A, Taing M-W. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. Res Social Adm Pharm. 2019;15:1014–1020.
   PubMed Web of Science ®Google Scholar
• Maguire MA, Pavlakos RN, Mehta BH, Schmuhl KK, Beatty SJ. A naloxone and harm reduction educational program across four years of a doctor of pharmacy program. Curr Pharm Teach Learn. 2018;10(1):72–77.
   PubMed Web of Science ®Google Scholar
• Rickles NM, Huang AL, Gunther MB, Chan WJ. An opioid dispensing and misuse prevention algorithm for community pharmacy practice. Res Soc Adm Pharm. 2019;15(8):959–965.
   PubMed Web of Science ®Google Scholar
• Schartel A, Lardieri A, Mattingly A, Feemster AA. Implementation and assessment of a naloxone-training program for first-year student pharmacists. Curr Pharm Teach Learn. 2018;10(6):717–722.
   PubMed Web of Science ®Google Scholar
• Skoy E, Eukel H, Frenzel J, Werremeyer A. Preparing student pharmacists to identify opioid misuse, prevent overdose and prescribe naloxone. Curr Pharm Teach Learn. 2019;11(5):522–527.
   PubMed Web of Science ®Google Scholar
• Skoy E, Werremeyer A. The opioid crisis—educating the next generation of pharmacists. Curr Pharm Teach Learn. 2019;11(5):431–432.
   PubMed Web of Science ®Google Scholar
• Strand MA, Eukel H, Burck S. Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk. Res Soc Adm Pharm. 2018;15:1032–1036
   PubMed Web of Science ®Google Scholar
• Tewell R, Edgerton L, Kyle E. Establishment of a pharmacist-led service for patients at high risk for opioid overdose. Am J Health Syst Pharm. 2018;75(6):376–383.
   PubMed Web of Science ®Google Scholar
• Thakur T, Frey M, Chewning B. Pharmacist services in the opioid crisis: current practices and scope in the United States. Pharmacy 2019;7(2):60.
   Web of Science ®Google Scholar
• Werremeyer A, Skoy E, Marvanova M, et al. A PharmD program curricular approach to addressing the opioid crisis. Curr Pharm Teach Learn. 2019;11(6):592–602.
   PubMed Web of Science ®Google Scholar
• AACP. Opioid-related activities [Webpage]. https://www.aacp.org/opioid. Accessed November 13, 2019.
   Google Scholar
• Sherwood DA, Kramlich D, Rodriguez K, Graybeal C. Developing a screening, brief intervention, and referral to treatment (SBIRT) program with multiple health professions programs. J Interprof Care. 2019;33(6):828–831.
   PubMed Web of Science ®Google Scholar
• Shonesy BC, Williams D, Simmons D, Dorval E, Gitlow S, Gustin RM. Screening, brief intervention, and referral to treatment in a retail pharmacy Setting: the pharmacist’s role in identifying and addressing risk of substance use disorder. J Addict Med. 2019;13(5):403–407.
   PubMedGoogle Scholar
• Cochran G, Field C, Karp J, et al. A community pharmacy intervention for opioid medication misuse: a pilot randomized clinical trial. J Am Pharm Assoc (2003). 2018;58(4):395–403.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Veterans Affairs. Tennessee Valley Healthcare System PGY2 Psychiatry Program [Webpage]. https://www.tennesseevalley.va.gov/careers/Pharmacy_PGY2_Psychiatry.asp. Accessed August 24, 2019.
   Google Scholar
• U.S. Department of Veterans Affairs. VA North Texas Health Care System [Webpage]. https://www.northtexas.va.gov/educ_affil/DALT.asp. Accessed August 24, 2019.
   Google Scholar
• College of Psychiatric and Neurologic Pharmacists. Psychiatric and neurologic pharmacy fellowships [Webpage]. https://cpnp.org/career/fellowships. Accessed August 24, 2019.
   Google Scholar
• Board of Pharmacy Specialties. Board of pharmacy specialties [Webpage]. https://www.bpsweb.org/. Accessed August 24, 2019.
   Google Scholar
• Dopheide JA, Bostwick JR, Goldstone LW, et al. Curriculum in psychiatry and neurology for pharmacy programs. Am J Pharm Educ. 2017;81(7):5925.
   PubMed Web of Science ®Google Scholar
• American Society of Health-System Pharmacists. Online residency directory [Webpage]. https://accred.ashp.org/aps/pages/directory/residencyprogramsearch.aspx. Accessed Augsut 24, 2019.
   Google Scholar
• Bureau of Labor Statistics. Current population survey [Webpage]. https://www.bls.gov/cps/cpsaat11.htm. Accessed August 19, 2019.
   Google Scholar
• American Association of Colleges of Pharmacy. Academic pharmacy’s vital statistics [Webpage]. https://www.aacp.org/article/academic-pharmacys-vital-statistics. Accessed August 24, 2019.
   Google Scholar
• Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007–2015. Plos One. 2017;12(8):e0183172.
   PubMed Web of Science ®Google Scholar
• Haines ST, Pittenger AL, Stolte SK, et al. Core entrustable professional activities for new pharmacy graduates. Am J Pharm Educ. 2017;81(1):S2.
   PubMed Web of Science ®Google Scholar
• Jungnickel PW, Desimone EM, Kissack JC, et al. Report of the AACP Special Committee on substance abuse and pharmacy education. Am J Pharm Educ. 2010;74(10):S11.
   PubMedGoogle Scholar
• American Association of Colleges of Pharmacy. Curricular Guidelines for Pharmacy - Substance Abuse and Addictive Disease. Arlington, VA: American Association of Colleges of Pharmacy; no date. https://www.aacp.org/sites/default/files/Curricular%20Guidelines%20for%20Pharmacy%20-%20Substance%20Abuse%20and%20Addictive%20Disease.pdf. Accessed August 24, 2019.
   Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019;380(24):2285. April
   PubMed Web of Science ®Google Scholar
• Dole EJ, Tommasello A. Recommendations for implementing effective substance abuse education in pharmacy practice. Subst Abus. 2002;23(sup1):263–271.
   PubMedGoogle Scholar
• Tommasello AC. Substance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependence. Harm Reduct J 2004;1(1):3.
   PubMedGoogle Scholar
• Al-Shatnawi SF, Perri M, Young HN, Norton M. Substance use attitudes, behaviors, education and prevention in colleges of pharmacy in the United States. Am J Pharm Educ. 2016;80(9):160.
   PubMed Web of Science ®Google Scholar
• Light KE, Goodner K, Seaton VA, Boyle B, Hopkins R. State programs assisting pharmacy professionals with substance use disorders. J Am Pharm Assoc. 2017;57(6):704–710.
   Google Scholar
• Polinski JM, Howell B, Gagnon MA, Kymes SM, Brennan TA, Shrank WH. Impact of CVS Pharmacy’s discontinuance of tobacco sales on cigarette purchasing (2012–2014). Am J Public Health. 2017;107(4):556–562.
   PubMed Web of Science ®Google Scholar
• Stover KA. APhA House of Delegates adopts 13 new policies. J Am Pharm Assoc (1996). 1996;36(6):394–396.
   Google Scholar
• APhA. Report of the 2010 APhA House of Delegates. J Am Pharm Assoc. 2010;50(4):471–472.
   Google Scholar
• APhA. Report of the 2005 APhA House of Delegates. J Am Pharm Assoc. 2005;45(5):554–560.
   Google Scholar
• APhA. Report of the 2014 APhA House of Delegates. J Am Pharm Assoc. 2014;54(4):357–368.
   Google Scholar
• American Society of Addiction Medicine. Nurse practitioners and physician assistants prescribing buprenorphine [Web page]. https://www.asam.org/resources/practice-resources/buprenorphine-waiver-management#NPPA. Accessed August 24, 2019.
   Google Scholar
• Andrilla CHA, Patterson DG, Moore TE, Coulthard C, Larson EH. Projected contributions of nurse practitioners and physicians assistants to buprenorphine treatment services for opioid use disorder in rural areas. Med Care Res Rev. 2018. doi: 10.1177/1077558718793070.
   Google Scholar
• Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108–112.
   Web of Science ®Google Scholar
• Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017;15(4):359–362.
   PubMed Web of Science ®Google Scholar
• Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26.
   PubMed Web of Science ®Google Scholar
• Provider status: what pharmacists need to know now. American Pharmacists Association. http://www.pharmacist.com/provider-status-what-pharmacists-need-know-now. Published August 2, 2013. Accessed February 8, 2017.
   Google Scholar
• Brooks VG, Brock TP, Ahn J. Do training programs work? An assessment of pharmacists activities in the field of chemical dependency. J Drug Educ. 2001;31(2):153–169.
   PubMed Web of Science ®Google Scholar
• Green TC, Mann MR, Bowman SE, et al. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc (2003). 2013;53(3):273–281.
   PubMed Web of Science ®Google Scholar
• Bloomberg American Health Initiative. http://americanhealth.jhu.edu/fentanyl.html. Accessed April 6, 2018.
   Google Scholar
• Corelli RL, Chai T, Karic A, Fairman M, Baez K, Hudmon KS. Tobacco and alcohol sales in community pharmacies: policy statements from U.S. professional pharmacy associations. J Am Pharm Assoc (2003). 2014;54(3):285–288.
   PubMed Web of Science ®Google Scholar
• Hagemeier NE, Tudiver F, Brewster S, Hagy EJ, Hagaman A, Pack RP. Prescription drug abuse communication: a qualitative analysis of prescriber and pharmacist perceptions and behaviors. Res Soc Adm Pharm. 2016;12(6):937–948.
   PubMed Web of Science ®Google Scholar
• Hagemeier NE, Tudiver F, Brewster S, et al. Interprofessional prescription opioid abuse communication among prescribers and pharmacists: a qualitative analysis. Subst Abuse. 2018;39:89–94.
   PubMed Web of Science ®Google Scholar
• Mahon LR, Hawthorne AN, Lee J, Blue H, Palombi L. Assessing pharmacy student experience with, knowledge of and attitudes towards harm reduction: illuminating barriers to pharmacist-led harm reduction. Harm Reduct J. 2018;15(1):57.
   PubMedGoogle Scholar
• Sattler S, Escande A, Racine E, Göritz AS. Public stigma toward people with drug addiction: a factorial survey. J Stud Alcohol Drugs. 2017;78(3):415–425.
   PubMed Web of Science ®Google Scholar
• van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen H. Healthcare professionals’ regard towards working with patients with substance use disorders: comparison of primary care, general psychiatry and specialist addiction services. Drug Alcohol Depend. 2014;134:92–98.
   PubMed Web of Science ®Google Scholar
• van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Comparing stigmatising attitudes towards people with substance use disorders between the general public, GPs, mental health and addiction specialists and clients. Int J Soc Psychiatry. 2015;61(6):539–549.
   PubMed Web of Science ®Google Scholar
• Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists’ decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc (Wash). 2002;42(6):S40–S45.
   PubMedGoogle Scholar
• Blumenthal WJ, Springer KW, Jones TS, Sterk CE. Pharmacy student knowledge, attitudes, and beliefs about selling syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6):S34–S39.
   PubMedGoogle Scholar
• Donovan E, Case P, Bratberg JP, et al. Beliefs associated with pharmacy-based naloxone: a qualitative study of pharmacy-based naloxone purchasers and people at risk for opioid overdose. J Urban Health. 2019;96(3):367.
   PubMed Web of Science ®Google Scholar
• Carpenter DM, Roberts CA, Westrick SC, et al. A content review of online naloxone Continuing Education courses for pharmacists in states with standing orders. Res Soc Adm Pharm. 2018;14(10):968–978.
   Web of Science ®Google Scholar
• Panther SG, Bray BS, White JR. The implementation of a naloxone rescue program in university students. J Am Pharm Assoc (2003). 2017;57(2):S107–S112.e2.
   PubMed Web of Science ®Google Scholar
• Franko TS, Distefano D, Lewis L. A novel naloxone training compared with current recommended training in an overdose simulation. J Am Pharm Assoc (2003). 2019;59(3):375–378.
   PubMed Web of Science ®Google Scholar
• Baez A. Development of an Objective Structured Clinical Examination (OSCE) for practicing substance abuse intervention competencies: an application in social work education. J Soc Work Pract Addict. 2005;5(3):3–20.
   Google Scholar
• Jacobson AN, Bratberg JP, Monk M, Ferrentino J. Retention of student pharmacists’ knowledge and skills regarding overdose management with naloxone. Subst Abuse. 2018;39(2):193–100. February
   PubMed Web of Science ®Google Scholar
• Dumenco L, Monteiro K, Collins S, et al. A qualitative analysis of interprofessional students’ perceptions toward patients with opioid use disorder after a patient panel experience. Subst Abuse. 2019;40:125–131.
   PubMed Web of Science ®Google Scholar
• Monteiro K, Dumenco L, Collins S, et al. An interprofessional education workshop to develop health professional student opioid misuse knowledge, attitudes, and skills. J Am Pharm Assoc (2003). 2017;57(2):S113–S117.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, George P, Scott NA, Dollase R, Tunkel AR, McDonald J. Access to treatment for opioid use disorders: medical student preparation: DATA Waiver for Medical Students. Am J Addict. 2017;26(4):316–318.
   PubMed Web of Science ®Google Scholar
• Hill LG, Sanchez JP, Laguado SA, Lawson KA. Operation Naloxone: overdose prevention service learning for student pharmacists. Curr Pharm Teach Learn. 2018;10(10):1348. doi:stigma.
   PubMed Web of Science ®Google Scholar
• Poole TM, Kodali L, Pace AC. Integrating medication therapy management education into a core pharmacy curriculum. Am J Pharm Educ. 2016;80(4):70.
   PubMed Web of Science ®Google Scholar
• Nuffer W, Gilliam E, Thompson M, Vande Griend J. Establishment and implementation of a required medication therapy management advanced pharmacy practice experience. Am J Pharm Educ 2017;81(2):36.
   PubMed Web of Science ®Google Scholar
• Feret B, Orr K, Bratberg J, MacDonnell C. Evaluation of immunization training in the curriculum of first- and third-year pharmacy students. Curr Pharm Teach Learn. 2015;7(4):541–545.
   Web of Science ®Google Scholar
• Siqueira L, Smith VC, Abuse C, On S. Binge drinking. Pediatrics 2015;136(3):e718–e726.
   PubMed Web of Science ®Google Scholar
• Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda, Board on Population Health and Public Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017.
   Google Scholar
• Hasin DS, O’Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. AJP. 2013;170(8):834–851.
   Google Scholar
• American Association of Colleges of Pharmacy. Core entrustable professional activities for new pharmacy graduates, appendix 1 [Web page]. https://www.aacp.org/sites/default/files/20170-10/Appendix1CoreEntrustableProfessionalActivities%20%281%29.pdf. Accessed August 24, 2019.
   Google Scholar
• Accreditation Council for Pharmacy Education. Guidance for standards 2016 [Web page]. https://www.acpe-accredit.org/pdf/GuidanceforStandards2016FINAL.pdf. Accessed August 24, 2019.
   Google Scholar
• Joint Commission of Pharmacy Practitioners. Pharmacists’ patient care process [Web page]. https://jcpp.net/wp-content/uploads/2016/03/PatientCareProcess-with-supporting-organizations.pdf. Accessed August 24, 2019.
   Google Scholar